Get the Stockscreener App
3.7122
6.02%
-0.2378
Nanobiotix Adr stock is traded at $3.7122, with a volume of 1,750.
It is down -6.02% in the last 24 hours and up +14.22% over the past month.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
See More
Previous Close:
$3.95
Open:
$3.94
24h Volume:
1,750
Relative Volume:
0.06
Market Cap:
$187.25M
Revenue:
$27,600
Net Income/Loss:
$-36.04M
P/E Ratio:
-4.6589
EPS:
-0.7968
Net Cash Flow:
$-1.66M
1W Performance:
-7.89%
1M Performance:
+14.22%
6M Performance:
-21.85%
1Y Performance:
-41.08%
1-Day Range:
$3.68
$3.94
1-Week Range:
$3.60
$4.00
52-Week Range:
$2.76
$7.51
Nanobiotix Adr Stock (NBTX) Company Profile
Compare NBTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
3.68 | 187.25M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.06 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.54 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.44 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.04 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.15 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | Guggenheim | Buy |
| Dec-08-23 | Initiated | Leerink Partners | Outperform |
| Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix Adr Stock (NBTX) Latest News
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study - MSN
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Mexico Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Latin America Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Middle East & Africa Chitosan Market Size & Outlook, 2030 - Grand View Research
The United States Chitosan Market Size & Outlook, 2030 - Grand View Research
China Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Japan Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
symbol__ Stock Quote Price and Forecast - CNN International
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
NBTX News Today | Why did Nanobiotix stock go up today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Nanobiotix Adr Stock (NBTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):